MTOR and cancer: In addition to mediating rapamycin’s clinical use for preventing graft rejection after organ transplantation and for treating autoimmune disorders, the components of the mTOR pathway have also been implicated in many other conditions including obesity related type 2 diabetes [105, 112, 148, 174, 175] and cancer [73, 182, 189].